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Background. Relationships between plasma morphine concentrations and neonatal responses
to endotracheal tube (ETT) suctioning are unknown in preterm neonates.
Methods. Ventilated preterm neonates (n=898) from 16 centres were randomly assigned to
placebo (n=449) or morphine (n=449). After an i.v. loading dose (100 mg kg21), morphine infu-
sions [23–26 weeks postmenstrual age (PMA) 10 mg kg21 h21; 27–29 weeks 20 mg kg21 h21;
and 30–32 weeks 30 mg kg21 h21] were established for a maximum of 14 days. Open-label
morphine (20–100 mg kg21) was given for pain or agitation. Morphine assay and neonatal
response to ETT suctioning was measured at 20–28 and 70–76 h after starting the drug infu-
sion and at 10–14 h after discontinuation of the study drug. The concentration–effect
response was investigated using non-linear mixed effects models.
Results. A total of 5119 data points (1598 measured morphine concentrations and 3521
effect measures) were available from 875 neonates for analysis. Clearance was 50% that of the
mature value at 54.2 weeks PMA (CLmat50) and increased from 2.05 litre h
21 70 kg21 at 24
weeks PMA to 6.04 litre h21 70 kg21 at 32 weeks PMA. The volume of distribution in preterm
neonates was 190 litre 70 kg21 (CV 51%) and did not change with age. There was no relation-
ship between morphine concentrations (range 0–440 mg litre21) and heart rate changes
associated with ETT suctioning or with the Premature Infant Pain Profile.
Conclusions. A sigmoid curve describing maturation of morphine clearance is moved to the
right in preterm neonates and volume of distribution is increased compared with term neo-
nates. Morphine does not alter the neonatal response to ETT suctioning.
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There are limited reports of either morphine pharmacoki-
netics (PK) or pharmacodynamics (PD) in preterm new-
borns. Chay and colleagues1 described a relationship
between morphine concentrations and the sedation required
to tolerate artificial ventilation in 19 neonates, both preterm
and term. Morphine produced sedation in 50% of patients
at concentrations of 125 mg litre21 and adverse effects at
.300 mg litre21. PK parameter estimates were not signifi-
cantly different between preterm and term neonates.1 Scott
and colleagues2 investigated the relationship between mor-
phine concentrations and heelstick-induced acute pain in
neonates (n¼48, 24–39 weeks PMA). Pain, assessed by the
Neonatal Facial Coding System, was unrelated to morphine
concentration. Morphine clearance increased from 2.27 (SD
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1.07) ml min21 kg21 at 24–27 weeks PMA to 7.8 (SD 2.67)
ml min21 kg21 at 36–39 weeks PMA.2
We had the opportunity to examine morphine PK–PD
data in preterm neonates enrolled in the NEOPAIN ran-
domized trial,3 with a larger sample size limited to the
lower gestational ages (23–32 weeks). We have previously
reported models describing morphine kinetics in term
infants.4 The data from that study has been pooled with
the NEOPAIN data3 and a new model developed in order
to broaden the range of the maturation models. This
current analysis uses a population-based approach that
included body size, expressed by weight, as the primary
covariate in an effort to disentangle age-related factors
from size-related factors.5 6
Methods
Study design
Preterm neonates were eligible for the NEOPAIN trial, if
they were born between 23 and 32 weeks of gestation and
required intubation before 72 h of age. Morphine infusion
was started within 8 h of intubation. Neonates with major
congenital abnormalities, birth asphyxia (5 min Apgar
score 3 or cord pH 7.0), intrauterine growth restriction
(5th percentile) or maternal opioid addiction, and those
participating in other clinical trials were excluded. Written
parental consent was obtained for all 898 neonates
enrolled from 16 neonatal intensive care units (NICUs)
and all clinical personnel were blinded to the study drug
code. The NEOPAIN protocol and consent forms were
approved by local ethics committees at each participating
site, by an external ethics committee at the coordinating
centre, and by an independent data and safety monitoring
board. Randomization via an automated telephone
response system was stratified according to participating
NICUs and gestational age (23–26, 27–29, or 30–32
weeks PMA) to ensure equal representation in the mor-
phine (n=449) and placebo (n=449) groups.
After an i.v. loading dose (100 mg kg21 infused over 1 h),
morphine infusions (23–26 weeks of gestation 10 mg kg21
h21; 27–29 weeks 20 mg kg21 h21; and 30–32 weeks
30 mg kg21 h21) were continued as long as clinically justi-
fied (maximum 14 days). Open-label morphine (20–100 mg
kg21 up to every 6 h) could be given, based on clinical
judgement (placebo group 242/443 and morphine group
202/446).
Study procedures
The neonatal response to endotracheal tube (ETT) suction-
ing was assessed by means of the Premature Infant Pain
Profile (PIPP). This assessment was performed before
starting morphine, during morphine infusion (at 20–28 h),
and 10–14 h after stopping morphine infusion. Heart rate
recorded before and after ETT suctioning was also avail-
able for analysis.
Arterial blood samples (1 ml) were collected for mor-
phine assay at 20–28 and 70–76 h after starting the drug
infusion and at 10–14 h after discontinuation of the study
drug. These blood samples were collected into pre-chilled
tubes containing sodium-EDTA, plasma obtained by
immediate centrifugation and stored at 2208C before
analysis.
Morphine analysis
All analyses were performed on a Hewlett-Packard model
5972B positive ion electron impact quadrupole mass spec-
trometer interfaced with a model 5890 gas chromatograph,
a model 6890 autosampler, and a Gateway model E-4200
computer using HP ChemStation Software (version
B.01.00). Each batch processed during the study contained
a set of six calibrators, viz., 500, 250, 125, 62.5, 31.25,
and 15.62 ng ml21, and four controls, viz., 400, 200, 30,
and 0 (drug-free plasma) ng ml21. Duplicate controls were
analysed in a randomized fashion in each of the 42 batch
runs during the 12 month period required for specimen
processing to assess precision and accuracy of the method.
If the determined concentration was .500 ng ml21, the
specimen was appropriately diluted and reprocessed. The
lower limit of quantitation was assumed to be 15.62 ng
ml21 (low calibrator) and the limit of detection was shown
by dilution of the low calibrator to be 1.95 ng ml21.
To 200 ml of patient plasma specimens, calibrators, or
controls were added 25 ml of d3-morphine internal stan-
dard solution and 400 ml of ammonium carbonate buffer
followed by brief vortex mixing. This mixture was slowly
added under reduced pressure to a 50 mg C-8 solid phase
column (Varian Bond Elut) that had been pre-washed with
21 ml methanol, 1 ml water, and 1 ml of ammonium
carbonate buffer under reduced pressure. Once the mixture
was adsorbed to the top of the solid phase column, the
reduced pressure was removed to accomplish equilibration
for 2 min. The column was washed with 1 ml of
ammonium carbonate buffer followed by 1 ml of methanol
under reduced pressure. The methanol elute was stored at
48C until GC-MS analysis.
For GC-MS analysis, the methanol elute was evaporated
to dryness under nitrogen at 508C. To the residue was
added 20 ml ethyl acetate (Aldrich) and 30 ml N,O-bis(tri-
methylsilyl)trifluoroacetamide (BSTFA, Pierce), the sol-
ution was then vortex mixed and heated in a sand bath at
758C for 15 min. After cooling to room temperature, the
resultant solution was transferred to an autosampler vial
for GC-MS analysis. An ethyl acetate blank was processed
after each specimen analysis. The gas chromatograph was
equipped with a capillary column (12 m0.2 mm ID, 0.33
mm film thickness) containing an HP-1 cross-linked
methyl silicone gum and operated using a programme with
an initial temperature of 1308C (2 min) that was increased
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to a final temperature of 2808C (1.28 min) at a rate of
31.88C min21 (total run time of 8.0 min). The carrier gas
was helium with an initial inlet pressure of 8.7 psi min21
and a flow rate of 1.0 ml min21. Detector temperature was
2808C. The injector port was operated at 1658C and fitted
with a Merlin septum and a glass mixing chamber assem-
bly containing a 10 mm silane-treated glass wool plug that
was 30 mm from the end next to the gold-plated seal
(bottom injector plate). The glass mixing chamber assem-
bly was changed daily and cleaned. The gold-plated seal
was changed at the time of column installation and ion
source cleaning. The mass spectrometer was auto-tuned
daily with perfluorotributylamine, was operated in the SIM
mode with a 50 ms dwell time, and was set at 400 V
greater than the multiplier value obtained in the daily
tune. Specimens were analysed monitoring the following
retention times and ions (where q is the quantitative ion):
d3-morphine, 7.19 min, m/z 432 (q), 433, 417 and mor-
phine, 7.20 min, m/z 429 (q), 430, 414. A ratio of qualifier
ions to quantitative ions of +20% was used for all ana-
lyses. The autosampler was set to perform five pumps of
the syringe before drawing 2 ml for injection. A viscosity
delay of 1 was used along with 10 washes of ethyl acetate.
Samples were injected in a splitless mode with a purge-on
time of 2 min followed by a 20:1 split.
Modelling
Model building and parameter estimation
Modelling of these data was performed using a non-linear
mixed effects model (NONMEM).7 This model accounts
for both between-subject and residual variability (random
effects) and parameter differences predicted by covariates
(fixed effects). The between-subject variability in the
model parameters (CL, V) was modelled by an exponential
between-subject variance model. The covariance between
clearance and distribution volume was incorporated into
the model. An additive and a proportional term character-
ized the residual unknown variability (Err). The population
geometric mean parameters, between-subject variance, and
residual variance were estimated using the first-order con-
ditional interaction estimation method and the ADVAN 3
TRANS 1 library module in NONMEM V. Convergence
criterion was three significant digits. A Fortran F77 compi-
ler (Watcom version 10.6) was used with an Intel Celeron
333 MHz CPU under MS Windows 2000.
Models were nested and the quality of fit of the model
to data was judged by the NONMEM objective function
(OBJ) and by visual examination of plots of observed vs
predicted values. A visual predictive check was used as a
model evaluation tool that gave reassurance that the model
could simulate the data that were used to build the model.
Bootstrap methods8 provided a means to evaluate par-
ameter uncertainty. A total of 1000 iterations were used to
estimate confidence intervals.
Data were supplied from two different sources for the
pooled population analysis and the between-study variabil-
ity was accounted for by giving each study separate
residual errors. Data from a previous study in postoperative
children (n=184, 0–3 yr)4 were included in the PK analy-
sis in order to compare parameter estimates in the preterm
neonates with a cohort of older children. The population
characteristics, procedure, and morphine assay methods in
the cohort group are described elsewhere.4 9 Just after
surgery, a loading dose of morphine (100 mg kg21 in 2
min) was given followed by either a continuous infusion
of morphine (10 mg kg21 h21) or an intermittent bolus
administration (30 mg kg21) every 3 h, and morphine con-
centrations were measured after the loading dose and at 6,
12, and 24 h after surgery.10 11
Pharmacokinetic model
The ADVAN 3 subroutine describes a two-compartment
disposition model. The model for morphine concentrations
was parameterized in terms of the central compartment
volume (V, litre) and total body clearance (CL, litre h21)
after i.v. administration. One compartment of the ADVAN
3 model was used to predict concentrations in the central
compartment. This one-compartment PK model is ade-
quate for sparsely sampled data and estimates will be
close to the true volume of distribution and clearance, but
only if sampling times are not too close to times at which
infusion rates are changed, as in this current study.
Arterial blood samples (1 ml) were collected for morphine
assay at 20–28 and 70–76 h after starting the drug infu-
sion and at 10–14 h after discontinuation of the study
drug.
Scaling for size
Many functional properties of the body such as metabolic
rate have a non-linear relationship to size.12 – 14 Parameter
values were standardized for a body weight of 70 kg using
an allometric power model.




where Pi is the parameter of the ith individual, Wi the
weight of the ith individual, and Pstd the parameter of an
individual with a weight Wstd. The PWR parameter was
0.75 for clearance and 1 for distribution.5 15
Age-related changes
The relationship between postmenstrual age (PMA) and












where CLstd (litre h21 70 kg21) is the population estimate
for CL, standardized to a 70 kg person using allometric
models; PMA the post-conception age in weeks; CLmat50
is the PMA at which clearance was 50% that of the mature
value; and HillCL the Hill coefficient that describes the
slope of clearance maturation. A scaling parameter,
FDEVCL, was applied to CLstd, if neonates were pre-
mature in order to investigate maturation differences from
term neonates, that is, FDEVCL was fixed at 1 for term
neonates and estimated for premature neonates.
The relationship between postnatal age (PNA) and PMA
and volume was investigated using the Hill equation and
an exponential function, for example.







V ¼ Vstd Wt
70
 




where Vstd (litre 70 kg21) is the population estimate for
V, standardized to a 70 kg person using allometric models;
Vmat50 the PMA at which volume was 50% that of the
mature value; HillV the Hill coefficient for V; bvol is a
parameter estimating the fractional difference from Vstd at
birth; and Tvol describes the maturation half-life of the
age-related changes of V. A scaling parameter, FDEVV,
was applied to Vstd for preterm ventilated neonates in
order to investigate volume of distribution differences
between preterm and term neonates.
Effect compartment model
An effect compartment accounted for effects and the
second ADVAN 3 compartment was used to predict effect
compartment concentrations. This effect compartment was
given a very small volume by scaling the first-order rate
constant for transfer from the central to the effect compart-
ment to 1/1000th that of the elimination rate constant from
the central compartment, so as not to influence the PK of
the central compartment. The equilibration half-time that
accounted for the delay between the central and the effect
compartment was fixed at 16 min using a prior estimated
by Inturrisi and colleagues17 because morphine was
administered as infusion and only three effect measure
assessments were made over for each individual over a
maximum of 14 days.
Pharmacodynamic model
PK and PD data were analysed simultaneously. The
relationships between morphine concentration and heart
rate changes or PIPP scores recorded with ETT suctioning
were modelled using exponential functions.
HRM ¼ HR0þ bHR expðSLOPEHR  CEÞ
PIPP ¼ bPIPP expðSLOPEPIPP CEÞ
where HRM is heart rate after ETT suctioning; HR0 heart
rate before suctioning; bHR and bPIPP are parameters
Table 1 PK and PD parameter estimates. These estimates are standardized to a 70 kg person using an allometric size model. %CV is the coefficient of variation
for the population parameter estimate; %SE, the standard error of the structural parameter estimate. CLstd (litre h21 70 kg21) is the population estimate for CL,
standardized to a 70 kg person using allometric models; Vstd (litre 70 kg21) is the population estimate for V, standardized to a 70 kg person using allometric
models; CLmat50 is the PMA at which clearance was 50% that of the mature adult value; HillCL is the Hill coefficient for clearance. A scale parameter,
FDEVCL, was applied to CLmat50 to preterm neonates in order to investigate maturation differences from term neonates; bvol is a parameter estimating the
fractional difference from Vstd at birth; Tvol describes the maturation half-life of the PNA age-related changes of V. A scale parameter, FDEVV was applied to
Vstd for preterm ventilated neonates in order to investigate volume of distribution differences. HR0 is heart rate before suctioning; bHR and bPIPP are
parameters describing the magnitude of the effect; SLOPEHR and SLOPEPIPP define the slopes for the relationships between morphine concentration in the
effect compartment (CE) and heart rate or PIPP changes before and after suctioning
Parameter Estimate %CV %SE 95% CI
CLstd 84.2 litre h21 70 kg21 48 6.9 73.3, 97.2
Vstd 122 litre 70 kg21 52 7.5 109, 161
CLmat50 54.2 weeks — 4.5 50.3, 60.5
HillCL 3.92 — 8.2 3.25, 4.40
FDEVCL 0.61 — 10.1 0.48, 0.78
Tvol 88.8 days — 90.9 54.6, 20
bvol 0.31 — 30.6 0.15, 0.48
FDEVV 1.56 — 10.3 1.14, 1.78
Err (proportional error) preterm 0.22% — 22 0.17, 0.30
Err (additive error) preterm 20.8 mg litre21 — 14.5 17.4, 23.8
Err (proportional error) term 0.34% 11.3 0.30, 0.37
Pharmacodynamic parameter estimates
HR0 147 beats min21 5.2 0.2 146, 148
bHR 4.23 — 14.2 3.09, 5.50
SLOPEHR 0.017 — 32.6 0.005, 0.029
bPIPP 8.71 — 1.4 8.48, 8.96
SLOPEPIPP 0.0005 62.9 42.5 0.0001, 0.0008
Err additive HR 14.5 beats min21 — 2.9 14.1, 15.0
Err proportional PIPP 0.36 units — 3.9 0.35, 0.37
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Fig 1 Quality of fit of pharmacokinetic data. (A) Displays individual Bayesian concentration predictions based on values of the parameters for the
specific individual. (B) Displays the predicted typical (population) concentrations, which are based on population parameters and covariate information.
(C) The y-axis displays the ratio of measured concentrations to those predicted from NONMEM post hoc, step-based on values of parameters for the
specific individual. (D) The y-axis displays the ratio of measured concentrations to those predicted from PK analysis. (E) The weighted residuals for
each subject in the two populations with values for each subject joined by vertical lines.
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describing the magnitude of the effect; and SLOPEHR
and SLOPEPIPP define the slopes for the relationships
between morphine concentration in the effect compartment
(CE) and heart rate changes before and after suctioning or
PIPP. Individual effects and parameters were obtained using
NONMEM’s maximum a posteriori Bayesian estimates.
Results
Blood sampling and successful morphine analyses
occurred in .97% of randomized preterm neonates
(n=875/898). These neonates had a PNA of 0.27 (SD 0.26,
range 0–2.84) weeks, PMA 27.35 (SD 2.31, range 23–32)
weeks, and weight 1.04 (SD 0.35, range 0.42–2.44) kg.
Full patient characteristic details are published elsewhere.3
A total of 5119 data points (1598 concentrations and 3521
effect measures) were available for analysis.
PK population parameters and PD estimates are shown
in Table 1. The quality of the fit is shown in Figure 1A–E.
Individual concentration predictions are based on values of
maximum a posteriori Bayesian estimates of the par-
ameters using the post hoc option, whereas predicted
typical (population) concentrations are based on popu-
lation parameters and covariate information. The corre-
lation of random effects for CL and V was 0.532.
Clearance increased from 2.05 litre h21 70 kg21 at 24
weeks PMA to 6.04 litre h21 70 kg21 at 32 weeks PMA
in preterm neonates and was associated with a CLmat50
29% (FDEVCL 0.61) less than that of neonates born at
term (Fig. 2A and B). The volume of distribution in
preterm neonates was 190 litre 70 kg21 (CV 51%) and did
not change with PMA or PNA in the premature popu-
lation. The relationship between volume and age was
investigated in term infants using both PMA (Fig. 3A
and B) and PNA (Fig. 4). PNA was used in the final model
for V because it proved superior to PMA (OBJ 11 230.626
vs 11 179.389). Table 2 shows the clearance estimates
using allometric and per kilogram size models.
There was no relationship between morphine concen-
tration (0–440 mg litre21) and heart rate changes associ-
ated with ETT suctioning (Fig. 5) or the PIPP scores
(Fig. 6).
Discussion
Morphine clearance in ventilated preterm neonates is
reduced compared with term neonates and current esti-
mates are comparable with those reported by Scott and
colleagues2 (Table 2), although more robust estimates and
data specific to lower gestational ages are available from
the current analysis. Clearance increases with gestation,
but it is thought birth stimulates further maturation of drug
metabolism.18 19 Our current data show a rightward shift
of morphine disposition in premature neonates (Fig. 2B)
and do not support a temporal switch occurring at birth.
Enzyme clearance systems, in general, appear to mature
and approximate adult levels within the first year of life.
There may be exceptions to this rule (e.g. N-acetyltransfer-
ase).20 Morphine clearance was 80% that of adults by 6
months and 96% that predicted in adults by 1 yr.4
Morphine is largely metabolized by uridine 50-diphos-
phate glucuronosyltransferase UGT2B7 to morphine-3-
glucuronide and morphine-6-glucuronide.21 Clearance
pathways become active before birth and in vitro studies
using liver microsomes from fetuses aged 15–27 weeks
indicated that morphine glucuronidation was approxi-
mately 10–20% of that seen with adult microsomes.22 23
We had no prior biological model for the change of clear-
ance with time (PMA), but assumed a sigmoid process,
which commonly underlies time varying processes in
biology. A first-order process was also fitted, but with
poorer fit. PMA was used, rather than PNA because of the
known in vitro data.22 23 This sigmoid process has been
used successfully to describe vancomycin clearance matu-
ration with PMA in preterm neonates24 and acyclovir
clearance maturation in term neonates and older infants.25
Although PMA may define the baseline glucuronosyltrans-
ferase activity, transition from the intrauterine to the extra-
uterine environment may accelerate many metabolic
enzyme activities.26 – 29 Consequently, we anticipated a
shift to the left for the clearance maturation curve in
preterm neonates. Instead, the clearance maturation curve
was shifted to the right in this cohort of preterm neonates.
This may reflect their severity of illness; a supposition


























































Fig 2 (A) Individual predicted clearances (CL) for morphine, standardized
to a 70 kg person, from the NONMEM post hoc step, are plotted against
PMA. The dashed line represents the non-linear relation between clearance
and age. (B) Magnification of (A) to reveal the shift to the right for
maturation of clearance in preterm neonates (solid line).


































































Fig 3 (A) Individual predicted volumes of distribution (V) for morphine, standardized to a 70 kg person, from the NONMEM post hoc step, are plotted
against PMA. The dashed line represents the non-linear relation between clearance and age. (B) Magnification of (A) to reveal increased V in






























Fig 4 The relationship between volumes of distribution (V) for morphine and PNA reveals increased V in ventilator-dependent preterm neonates with
no relationship to PNA (solid line).
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maturation occurs more quickly in infants undergoing non-
cardiac surgery than those undergoing cardiac surgery30
and also the reduced clearance reported in critically ill
neonates.31 32
We also anticipated a reduced volume of distribution in
preterm neonates. Studies such as those by Pokela and
colleagues31 and Bouwmeester and colleagues4 describe
volume of distribution increasing from 91 (SD 28) litre
70 kg21 in neonates 1–4 days old, to 126 (SD 56) litre
70 kg21 at 8–60 days, and 168 (SD 105) litre 70 kg21 at
61–180 days of age. In order to investigate the effects of
PMA and PNA on the volume of distribution, premature
data from the NEOPAIN Study3 were anchored with refer-
ence to distal maturational changes in term neonates and
older infants studied by Bouwmeester and colleagues.4
Both PMA and PNA adequately described the volume of
distribution changes with age (Figs 3 and 4), but preterm
ventilated neonates had a higher volume of distribution,
with extremely high values noted among the more imma-
ture neonates, particularly on day 2 and around day 5 after
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Fig 5 The lack of relationship between morphine concentrations and heart rate changes occurring with ETT suctioning.
Table 2 Clearance estimates expressed as allometric and per kilogram.
*Weight is an estimate only
PMA Weight (kg)* CLstd (litre
h21 70 kg21)





24 0.5 2.06 1.68
26 0.8 2.79 2.03 2.27
28 1.0 3.69 2.54
30 1.5 4.77 2.97 3.21
32 2.0 6.04 3.50
34 2.4 7.50 4.16 4.51
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size, fat and muscle contents, binding affinity for plasma
and tissue proteins, or the lipid/water solubility partition
coefficient of morphine, all contribute to changes in the
volume of distribution with age. Fluid balance alterations
due to accumulation of extracellular fluid volume, associ-
ated with poor renal function and i.v. fluid resuscitation
just after birth, or fluid accumulation due to patent ductus
arteriosus at 5–7 days of age, or capillary leak due to
sepsis, or inappropriate antidiuretic hormone and altered
renal function in ventilated neonates may contribute to this
observation.
Size has considerable impact on the estimation and
interpretation of PK parameters in neonates6 15 and is often
unaccounted for in neonatal pharmacokinetic studies.6 Size
was the primary covariate used in our analysis of the effects
of age and weight. This deliberate choice was based on
known biological principles. A great many physiological,
structural, and time-related variables scale predictably
within and between species with weight exponents of 0.75,
1, and 0.25, respectively.12 We have used these ‘1/4 power
models’ in this current study rather than centred weight, or
some other function of weight, because the ‘1/4 power
models’ are based on sound biological principles.16 West
and colleagues13 14 have used fractal geometry to mathemat-
ically explain this phenomenon. The 3/4 power law for
metabolic rates was derived from a general model that
describes how essential materials are transported through
space-filled fractal networks of branching tubes.13 14 These
design principles are independent of detailed dynamics and
explicit models and should apply to virtually all organisms.
By choosing weight as the primary covariate, the effects of
age independent of size could be investigated.16
The NEOPAIN study noted that heart rate was lower in
the morphine group than in the placebo group after ETT
suctioning at 20–28 h.3 PIPP scores from ETT suctioning at
20–28 h were also lower in the morphine group than in the
placebo group. Target analgesic plasma concentrations are
believed to be 10–20 mg litre21 after major surgery,30 33
although higher concentrations of 125 mg litre21 were
required to produce sedation during mechanical ventilation
in 50% of neonates.1 Despite having peak plasma concen-
trations of up to 440 mg litre21, this study was unable to
establish any relationship between morphine concentrations
and analgesic effects (Figs 5 and 6). Individual heart rate
and PIPP changes were examined using population model-
ling rather than the aggregates taken in earlier studies.34 35
The PIPP scoring system appears well suited for the acute
pain caused by tissue injury (e.g. heelstick), but not for ETT
suctioning.3 36 Prolonged or subacute neonatal pain may
require novel assessment approaches.37 On the other hand,
morphine may not be an appropriate sedative or analgesic
for ETT suctioning either, which is an irritating stimulus,
often associated with vagal slowing of the heart rate in
preterm neonates. Other studies also suggest that morphine
lacks any analgesic effects in neonates exposed to heelsticks
or ETT suction.36 38 Other sedatives were not given to
preterm neonates in this study, so drug interactions are
unlikely to explain this response.
In summary, using population PK–PD modelling in
ventilated preterm neonates who were treated with placebo
or morphine infusions and intermittent morphine boluses,
we report maturational changes in morphine clearance
occurring at 23–32 weeks gestation (with a shift to the
right in the clearance maturational curve) and higher
volume of distribution in preterm neonates than in term
neonates or older infants. We also noted no evidence of
morphine analgesic effects in relation to ETT suction, par-
ticularly when measured by heart rate changes and PIPP
scores. Pain, assessed by the Neonatal Facial Coding
System, was also unrelated to morphine concentration in
the study by Scott and colleagues.2 This not only calls
into question the validity of these measures of pain, but
also the efficacy of morphine analgesia in preterm neo-
nates. Further analyses from this data set can be designed
to examine the effects of morphine infusion on respiratory
function, because of reduced ventilatory frequencies and
longer ventilation reported in the NEOPAIN trial,3 and
also whether the intermittent morphine doses, given to
some neonates in both randomized groups, contributed to
an increased incidence of poor neurological outcomes in
ventilated preterm neonates.3 39
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